Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-24 in Healthy Adults
NCT05266456Phase 2Completed
- Sponsor
- Vaxcyte
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 24-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD), sponsored by Vaxcyte. Started Feb 2022; status: completed.
02
Drugs
24-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT05266456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266456.